Introduction: Bipolar disorder type I (BD-I) is characterized by a severe impairment in emotional processing during both acute and euthymic phases of the illness. The aim of the present study was to investigate negative emotion processing in both euthymic patients and non-affected first-degree relatives, looking for state and trait markers of BD-I.

Methods: 22 healthy relatives of BD-I patients (mean age 31.5±7.3 years; 15 females), 23 euthymic BD-I patients (mean age 35.2±7.9 years; 14 females), and 24 matched controls (mean age 32.5±6.2 years; 16 females) performed an IAPS-based emotional task during 1.5T fMRI. They were required to identify vegetable items (targets) inside neutral or negative pictures.

Results: Euthymic BD-I patients showed a significant reduced accuracy in target detection during both neutral and negative images presentation, whereas first-degree relatives performed similarly to normal comparisons. We found a reduced activation of Left precuneus during negative images condition in the patients only. By contrast, both patients and relatives hyperactivated the Left insula and hypoactivated the Right supramarginal gyrus with respect to controls. Moreover, relatives showed an increased activation of Right lingual gyrus and lower activation of pre-supplementary motor area and Right superior frontal gyrus.

Conclusions: During a negative emotion task, euthymic BD-I patients and non-affected first-degree relatives shared an abnormal activation of a limbic area (Left insula) coupled with a reduced activation of a parietal region (Right supramarginal gyrus), thus suggesting a trait-like anomalous processing of affective contents. On the other hand, functional abnormalities found only in unaffected relatives and not in patients and controls may correspond to resilience factors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pnpbp.2015.01.016DOI Listing

Publication Analysis

Top Keywords

bd-i patients
16
negative emotion
12
first-degree relatives
12
years females
12
euthymic bd-i
12
emotion processing
8
bipolar disorder
8
patients
8
patients non-affected
8
non-affected first-degree
8

Similar Publications

Objective: In recent years, there has been a rapid increase in reports upon social-cognition impairments in bipolar disorder. This study aimed to compare the characteristics of social cognition domains in bipolar I (BD I) and II (BD II) based on the findings to date.

Methods: A systematic literature search was conducted on Web of Science and PubMed from inception to 28 August 2024.

View Article and Find Full Text PDF

Background: There is lack of data on bipolar disorder (BD) type II from India.

Aim: To compare the demographic and clinical characteristics of patients with BD-I and BD-II using the data of the Bipolar Disorder Course and Outcome study from India (BiD-CoIN study).

Methodology: Using the data of the BiD-CoIN study, patients with BD-I and BD-II were compared for demographic and clinical variables.

View Article and Find Full Text PDF

The neural correlates of guilt highlight preclinical manifestations between bipolar and major depressive disorders.

Compr Psychiatry

February 2025

Department of Physical Medicine and Rehabilitation, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan; Institute of Neuroscience and Brain Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Education and Research, Taipei City Hospital, Taipei, Taiwan. Electronic address:

Background: Over 25 % of bipolar disorder (BD) patients are misdiagnosed with major depressive disorder (MDD). An urgent need exists for a biomarker to differentiate BD from MDD. Various manifestations and intensities of maladaptive guilt processing might uniquely contribute to the pathogenesis of BD compared to MDD.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the long-term safety, tolerability, and effect of olanzapine/samidorphan (OLZ/SAM) in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder for up to 4 years, following the ENLIGHTEN clinical program.
  • - Out of 524 enrolled patients, the majority had schizophrenia, and common adverse effects included weight gain, headache, and anxiety, with minimal changes in metabolic parameters over the treatment duration.
  • - The treatment showed stable scores on the Clinical Global Impressions-Severity scale, indicating maintained symptom control and a long-term safety profile consistent with previous studies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!